** Drug developer Summit Therapeutics' SMMT.O shares rise 4.9% to $21.23 premarket
** Citigroup upgrades to "buy" from "neutral" citing strong confidence in HARMONi-2 trial for cancer drug ivonescimab, with chance of favorable results by end of 2025
** Last month, co announced a collaboration with Pfizer PFE.N to study ivonescimab in combination with Pfizer's antibody drug conjugates (ADCs) across various tumor types
** Brokerage says trial success could make ivonescimab a groundbreaking therapy in NSCLC (non-small cell lung cancer)
** $35 PT for Summit represents ~53% upside to last close
** Analysts' average rating is equivalent of "buy"; median PT $44 - data compiled by LSEG
** Shares rose 13.4% YTD vs 12.5% increase in S&P 500 biotechnology index .SPLRCTKBI
(Reporting by Rashika Singh in Bengaluru)
((rashika.singh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.